RxDoctor Payments Data

Edward Lafleur, MD

Family Medicine · Youngsville, LANPI 1629050398

Payments from drug & device makers

$1,067in general payments, 2019–2025

Across 50 payments — averaging $21.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$380
  • Coloplast$178
  • Lilly USA, LLC$125
  • Alkermes, Inc.$95
  • Getinge USA Sales, LLC$80
  • Novo Nordisk$41
  • plus $167 from 8 others

What the payments were for

  • Food & beverage$1,067100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,067 in reported general payments places this provider in the 55th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$20,492
Medicare patients
87
Services billed
223

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide25$31,041
MounjaroTirzepatide16$28,957
JardianceEmpagliflozin25$20,978
OzempicSemaglutide14$13,344
Breo ElliptaFluticasone/Vilanterol27$10,516
SymbicortBudesonide/Formoterol Fumarate11$6,558
SynthroidLevothyroxine Sodium23$1,128
Valsartan46$1,050
Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide30$839
Rosuvastatin Calcium56$774
Armour ThyroidThyroid,pork14$754
Levothyroxine Sodium53$615
Tamsulosin Hcl30$424
Escitalopram Oxalate26$396
Liothyronine Sodium14$370

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$125$59,99841 claims
Novo NordiskOzempic$41$13,34414 claims
GSKBreo Ellipta$24$10,51627 claims
AbbVieSynthroid, Armour Thyroid$380$1,88237 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$15$61553 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Youngsville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →